Recipharm and Moderna finalized agreement for aseptic drug manufacturing and fill-finish for countries outside the U.S.
On Dec. 30, 2020, Moderna announced that they had reached an agreement to support formulation and fill-finish a part of the Moderna COVID-19 Vaccine supply outside of the U.S. The activity will be performed in Recipharm’s drug product manufacturing facility located in France.
Subject to regulatory approval of the vaccine in relevant countries outside of the U.S., it was anticipated that supply would commence in early 2021.
Tags:
Source: Moderna
Credit:
